Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (11-20 of 205) with videos related to

Pageof 21
Sort By:
Hematology. American Society of Hematology. Education Program|December 4, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P Hughes
Blood|February 21, 2020
What's NEXT for CML-NGS mutation screeningNaranie Shanmuganathan, Timothy P Hughes
Leukemia & Lymphoma|July 8, 2008
How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?David M Ross, Timothy P Hughes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib responseDeborah L White, Timothy P Hughes
Leukemia & Lymphoma|April 6, 2012
Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitorsDevendra K Hiwase, Timothy P Hughes
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Strategies for the treatment of imatinib-resistant chronic myeloid leukemiaChi-hung Hui, Timothy P Hughes
Annals of Internal Medicine|October 5, 2018
Treatment-Free Remission After Second-Line Nilotinib TreatmentFrançois-Xavier Mahon, Timothy P Hughes
British Journal of Haematology|November 10, 2020
Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challengeDavid M Ross, Timothy P Hughes
Blood|March 26, 2016
Moving treatment-free remission into mainstream clinical practice in CMLTimothy P Hughes, David M Ross
Nature Reviews. Clinical Oncology|February 8, 2017
Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CMLTimothy P Hughes, David M Ross
Pageof 21

Showing results (11-20 of 205) with videos related to

Sort By:
Pageof 21
Hematology. American Society of Hematology. Education Program|December 4, 2018
Molecular monitoring in CML: how deep? How often? How should it influence therapy?Naranie Shanmuganathan, Timothy P Hughes
Blood|February 21, 2020
What's NEXT for CML-NGS mutation screeningNaranie Shanmuganathan, Timothy P Hughes
Leukemia & Lymphoma|July 8, 2008
How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?David M Ross, Timothy P Hughes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2012
Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib responseDeborah L White, Timothy P Hughes
Leukemia & Lymphoma|April 6, 2012
Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitorsDevendra K Hiwase, Timothy P Hughes
Clinical Advances in Hematology & Oncology : H&O|November 1, 2005
Strategies for the treatment of imatinib-resistant chronic myeloid leukemiaChi-hung Hui, Timothy P Hughes
Annals of Internal Medicine|October 5, 2018
Treatment-Free Remission After Second-Line Nilotinib TreatmentFrançois-Xavier Mahon, Timothy P Hughes
British Journal of Haematology|November 10, 2020
Counterpoint: There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challengeDavid M Ross, Timothy P Hughes
Blood|March 26, 2016
Moving treatment-free remission into mainstream clinical practice in CMLTimothy P Hughes, David M Ross
Nature Reviews. Clinical Oncology|February 8, 2017
Targeted therapies: Remembrance of things past - discontinuation of second-generation TKI therapy for CMLTimothy P Hughes, David M Ross
Pageof 21